Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
- PMID: 20801772
- DOI: 10.1136/gut.2010.216077
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
Abstract
Background: Accurate evaluation of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is important to identify patients who may develop complications. The aim of this study was to compare the diagnostic performance of simple non-invasive tests in identifying advanced fibrosis among patients with biopsy-proven NAFLD.
Methods: Consecutive patients with biopsy proven NAFLD were recruited from the Newcastle Hospitals Fatty Liver Clinic from 2003 to 2009. The AST/ALT ratio, AST to platelet ratio index, BARD (weighted sum of BMI>28=1 point, AST/ALT ratio>0.8=2 points, diabetes=1 point), FIB-4 (agexAST (IU/l)/platelet count (x10(9)/litre)x radicalALT (IU/l)) and NAFLD fibrosis scores were calculated from blood tests taken at time of biopsy.
Results: 145 patients (82 male (61%), mean age 51+ or -12 years) were included. The mean body mass index was 35+ or -5 kg/m(2). 73 subjects (50%) had diabetes. 93 patients (64%) had non-alcoholic steatohepatitis. 27 (19%) had advanced fibrosis (Kleiner stage 3-4). The FIB-4 score had the best diagnostic accuracy for advanced fibrosis (area under receiver operator characteristic curve (AUROC) 0.86), followed by AST/ALT ratio (AUROC 0.83), NAFLD fibrosis score (AUROC 0.81), BARD (AUROC 0.77) and AST to platelet ratio index (AUROC 0.67). The AST/ALT ratio, BARD score, FIB-4 and NAFLD fibrosis scores had negative predictive values greater than 90% (93%, 95%, 95% and 92% respectively). Positive predictive values were modest. In order to exclude advanced fibrosis liver biopsy could potentially be avoided in 69% with AST/ALT ratio, 62% with FIB-4, 52% with NAFLD fibrosis score and 38% with BARD.
Conclusions: The ALT/AST ratio, FIB-4 and NAFLD fibrosis scores can reliably exclude advanced fibrosis in a high proportion of patients with NAFLD, allowing liver biopsy to be used in a more directed manner.
Similar articles
-
Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8. doi: 10.1097/MEG.0b013e32835d72cf. Eur J Gastroenterol Hepatol. 2013. PMID: 23325287
-
Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease.J Hepatol. 2011 Jan;54(1):160-3. doi: 10.1016/j.jhep.2010.06.028. Epub 2010 Aug 22. J Hepatol. 2011. PMID: 20934232
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.J Gastroenterol Hepatol. 2011 Oct;26(10):1536-43. doi: 10.1111/j.1440-1746.2011.06774.x. J Gastroenterol Hepatol. 2011. PMID: 21950746
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.Aliment Pharmacol Ther. 2013 Feb;37(4):392-400. doi: 10.1111/apt.12186. Epub 2012 Dec 20. Aliment Pharmacol Ther. 2013. PMID: 23278163 Review.
-
Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease.Ann Hepatol. 2009 Apr-Jun;8(2):89-94. Ann Hepatol. 2009. PMID: 19502649 Review.
Cited by
-
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.Diagnostics (Basel). 2023 Oct 26;13(21):3316. doi: 10.3390/diagnostics13213316. Diagnostics (Basel). 2023. PMID: 37958212 Free PMC article. Review.
-
MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis.Eur Radiol. 2012 Jun;22(6):1224-32. doi: 10.1007/s00330-012-2378-5. Epub 2012 Feb 3. Eur Radiol. 2012. PMID: 22302503
-
Performance of the Bard Scoring System in Bariatric Surgery Patients with Nonalcoholic Fatty Liver Disease.Obes Surg. 2017 Feb;27(2):394-398. doi: 10.1007/s11695-016-2284-z. Obes Surg. 2017. PMID: 27392972
-
Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography.Eur J Gastroenterol Hepatol. 2024 Apr 1;36(4):476-481. doi: 10.1097/MEG.0000000000002713. Epub 2024 Feb 16. Eur J Gastroenterol Hepatol. 2024. PMID: 38407839
-
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.Clin Mol Hepatol. 2024 Sep;30(Suppl):S5-S105. doi: 10.3350/cmh.2024.0506. Epub 2024 Aug 19. Clin Mol Hepatol. 2024. PMID: 39159947 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical